Most people treat calcium as a single mineral — take more of it, and your bones benefit. But the form calcium takes matters as much as the amount. This article compares three distinct approaches to bone health: conventional calcium supplements, SAC® (Sigma Anti-bonding Calcium Carbonate), and prescription osteoporosis medications.
The thread that ties them together is ionized calcium: the free, unbound fraction circulating in the blood that the body's own regulatory system responds to. Conventional supplements rely on bulk intake — hundreds of milligrams per dose, much of it bound to protein and rendered inactive once absorbed. Osteoporosis medications bypass that system entirely, acting directly on bone cells. SAC® takes a third route: a small quantity of calcium already in active, ionized form, feeding the hormonal system that governs whether bone is being built or broken down.
WHAT IS IONIZED CALCIUM?
Ionized calcium is the free, unbound calcium circulating in the blood, and it is the physiologically active fraction. Roughly half the calcium in circulation is bound to plasma proteins, and that bound fraction is inert — it doesn't participate in the body's calcium signalling. This is why clinical laboratories measure ionized calcium separately from total calcium: total calcium describes how much is present, ionized calcium describes how much is available to act. That distinction is the foundation of everything that follows, because SAC® is designed around the active fraction rather than the total.
HOW BONE REMODELING WORKS
Bone is not static. It is continuously resorbed by osteoclasts and rebuilt by osteoblasts, and the balance between those two cell populations is governed hormonally, with serum ionized calcium as one of the primary inputs. The calcium-sensing receptor reads the ionized calcium concentration in circulation: when it falls, parathyroid hormone rises and bone resorption increases to restore balance; when ionized calcium is sufficient, that resorptive signal eases. Separately, extracellular calcium acts on bone marrow mesenchymal stem cells, amplifying BMP-2 signalling through the SMAD pathway and encouraging differentiation toward mature, bone-building osteoblasts.
CONVENTIONAL VS SAC®
How Is SAC® Different From Conventional Calcium Supplements?
Conventional calcium supplementation is based on bulk mineral intake, typically hundreds of milligrams of elemental calcium per dose — absorption from a mineral salt is partial, so intake is scaled up to compensate. Much of what gets through binds immediately to albumin and becomes physiologically inactive. SAC®'s sigma anti-bonding structure holds calcium weakly, letting it form coordination bonds with water so it enters circulation passively, as free ionized calcium — without depending on vitamin D and without binding to albumin on arrival.
Conventional Calcium Supplement
A story of scale: dosing high enough to compensate for partial, protein-bound uptake.
SAC®
A story of form: arriving already active, at a fraction of the elemental dose.
SAC® VS PRESCRIPTION TREATMENT
How Does SAC® Compare With Osteoporosis Medication?
Osteoporosis medications act on bone cells directly and pharmacologically, falling into two broad groups. Antiresorptives suppress the cells that break bone down: bisphosphonates bind to bone mineral and impair osteoclast function, denosumab blocks the RANKL signal osteoclasts need to form and survive, and selective estrogen receptor modulators act through estrogen pathways to slow resorption. Anabolics stimulate formation instead — teriparatide is a parathyroid hormone analogue given intermittently to drive osteoblast activity, and romosozumab inhibits sclerostin, releasing a brake on bone formation. These are effective, well-evidenced treatments prescribed on the basis of individual fracture risk, with defined risk profiles a clinician weighs against that risk.
Nutritional calcium does not work this way. It does not bind to a molecular target or suppress a cell population — it supplies the regulatory system with what that system uses to make its own decisions. That is why the effect is homeostatically buffered, why it tracks intake rather than persisting after withdrawal, and why the tolerability profile is fundamentally different from a prescribed medication.
SIDE BY SIDE
Comparison at a Glance
| Attribute | Conventional Calcium Supplement | SAC® | Osteoporosis Medication |
|---|---|---|---|
| Category | Nutritional supplement | Nutritional supplement | Prescription medicine |
| Design model | Bulk mineral intake | Delivery of calcium in ionic form | Direct pharmacological action on bone cells |
| Typical dose scale | Hundreds of mg elemental calcium | Milligram scale | Fixed prescribed dose |
| Absorption route | Active transport at low intake; passive at high intake | Passive; not vitamin-D-dependent | Oral, injection, or infusion depending on agent |
| Form in circulation | Substantially albumin-bound | Free ionized fraction | Not applicable |
| Mode of influence on bone | Supplies mineral substrate | Raises available ionized calcium, feeding the regulatory loop | Targets osteoclast or osteoblast activity directly |
| Effect after stopping | Gradual return to baseline | Returns to baseline | Varies; some require managed transition |
| Prescription required | No | No | Yes |
See references for supporting studies on ionized calcium, bone remodeling mechanisms, and osteoporosis pharmacotherapy.
WHAT THE RESEARCH SHOWS — PRECLINICAL
In animal models, a single oral dose of SAC® raised serum ionized calcium within an hour and held it elevated for several hours, while an equivalent dose of standard calcium carbonate produced no measurable change; repeated dosing sustained the elevation. Treated animals showed increased mineralization, higher bone volume, elevated bone-formation markers, and a shift toward more osteoblasts and fewer osteoclasts. When SAC® was withdrawn, serum calcium and the bone gains returned toward baseline — consistent with SAC® working through the body's own regulation rather than overriding it. This pattern was seen across an ovariectomized rat model and more extensive mouse studies, including immunodeficient and immune-competent models.
WHAT THE RESEARCH SHOWS — HUMAN
A retrospective study published in 2025 followed 82 adults at a clinic in Vancouver through approximately eight months of daily SAC®, measuring bone density at the distal radius by quantitative ultrasound. Mean T-score improved from −2.0 to −0.85; mean BMD rose from 0.95 to 1.10 g/cm²; speed of sound increased from 3,946 to 4,079. All three changes reached statistical significance across every age group and both sexes, with the largest gains among participants who started in the osteoporotic range. Sixty-five percent of participants who began with osteopenia moved into the normal range, and 64% of those who began with osteoporosis improved to osteopenia. This is early evidence: retrospective, single-site, ultrasound-based rather than DXA, and without a control arm — the authors themselves call for prospective randomized trials with DXA endpoints.
WHAT IS KNOWN ABOUT TOLERABILITY
Across the studies conducted to date, no overt toxicity has been observed under the conditions tested. In the mouse work, animals on SAC® for eight weeks excreted more calcium in urine — consistent with normal renal clearance of surplus — with no evidence of stone formation on imaging and no significant difference in kidney function markers versus controls. In the ovariectomized rat model, no adverse effects were reported, and across eight months in the human study, no adverse events were reported among the 82 participants.
Calcium is still a mineral the body holds within a narrow range, and intake well above requirement can raise blood calcium and stone risk in any form. If you have kidney disease, a history of stones, hypercalcemia, or a parathyroid condition, talk to your clinician first.
Frequently Asked Questions
Ionic Calcium, Bone Remodeling, and SAC®
The free, unbound form of calcium in the blood — the physiologically active fraction the body's regulatory system responds to. Calcium bound to albumin is inert.
SAC® is more than a high-absorption calcium. Its main difference is the form the calcium arrives in and how little of it is needed — milligrams in ionic form rather than hundreds of milligrams of mineral salt.
No. Conventional calcium relies substantially on the vitamin-D-dependent active transport pathway. SAC®'s hydrated ionic form is absorbed passively, so it does not depend on vitamin D status the way a mineral salt does.
No. Bisphosphonates, denosumab, SERMs, and anabolic agents act directly on bone cells. SAC® raises available ionized calcium and works through the body's own regulatory system.
Not with a regular calcium supplement — intake above requirement is not associated with proportionally greater benefit and can raise the risk of high blood calcium and kidney stones. SAC®'s milligram-scale dosing is designed with this in mind, but the same general caution around total calcium intake still applies.
A Note on Prescribed Treatment
If you are on a prescribed osteoporosis treatment, do not stop or change it without speaking to your physician. Some agents — denosumab in particular — require a planned transition, and stopping abruptly can lead to rapid bone loss.
Disclaimer
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any new supplement. Marah Natural products are not intended to diagnose, treat, cure, or prevent any disease, and statements have not been evaluated by the FDA or Health Canada.
References
Yoon D, Lee A, Yusuf I, et al. A potent calcium dietary consumption improves bone mineral density in Asian older adults. J Family Med Prim Care Open Acc. 2025;9:290. Choi SY, Park D, Yang G, et al. Effects of Sigma Anti-bonding Molecule Calcium Carbonate on bone turnover and calcium balance in ovariectomized rats. Lab Anim Res. 2011;27(4):301–307. Mehdi SH, Lee D, Lee A, et al. Sigma anti-bonding calcium carbonate as a novel dietary intervention. University of Arkansas for Medical Sciences (manuscript in preparation). Aquino-Martínez R, Artigas N, Gámez B, et al. Extracellular calcium promotes bone formation from bone marrow mesenchymal stem cells by amplifying the effects of BMP-2 on SMAD signalling. PLoS One. 2017;12(5):e0178158. Brown EM. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev. 1991;71(2):371–411. Tang BML, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–666. [SKKU study — citation still needed, do not publish without it].